Thioridazine, Prolongatum en es it fr

Thioridazine, Prolongatum Brand names, Thioridazine, Prolongatum Analogs

Thioridazine, Prolongatum Brand Names Mixture

  • No information avaliable

Thioridazine, Prolongatum Chemical_Formula

C21H26N2S2

Thioridazine, Prolongatum RX_link

http://www.rxlist.com/cgi/generic3/thioridazine.htm

Thioridazine, Prolongatum fda sheet

Thioridazine, Prolongatum msds (material safety sheet)

Thioridazine,_Prolongatum MSDS

Thioridazine, Prolongatum Synthesis Reference

Bourquin et al., Helv. Chim. Acta 41, 1072 (1958)

Thioridazine, Prolongatum Molecular Weight

370.577 g/mol

Thioridazine, Prolongatum Melting Point

73 oC

Thioridazine, Prolongatum H2O Solubility

0.0336 mg/L

Thioridazine, Prolongatum State

Solid

Thioridazine, Prolongatum LogP

6.552

Thioridazine, Prolongatum Dosage Forms

Suspension; Tablet

Thioridazine, Prolongatum Indication

For the treatment of schizophrenia and generalized anxiety disorder.

Thioridazine, Prolongatum Pharmacology

Thioridazine is a trifluoro-methyl phenothiazine derivative intended for the management of schizophrenia and other psychotic disorders. Thioridazine has not been shown effective in the management of behaviorial complications in patients with mental retardation.

Thioridazine, Prolongatum Absorption

60%

Thioridazine, Prolongatum side effects and Toxicity

LD50=956-1034 mg/kg (Orally in rats); Agitation, blurred vision, coma, confusion, constipation, difficulty breathing, dilated or constricted pupils, diminished flow of urine, dry mouth, dry skin, excessively high or low body temperature, extremely low blood pressure, fluid in the lungs, heart abnormalities, inability to urinate, intestinal blockage, nasal congestion, restlessness, sedation, seizures, shock

Thioridazine, Prolongatum Patient Information

Thioridazine, Prolongatum Organisms Affected

Humans and other mammals